Sermorelin Dosing and Administration

Before You Start: Who Sermorelin Is Not For

This belongs ahead of any discussion of timing or technique, and it is routinely missing from pages about sermorelin dosing.

There is no FDA-approved label for compounded sermorelin, so there is no official contraindication list to quote. Tesamorelin has one, because it is an approved finished product; sermorelin's historical GEREF approvals were withdrawn in 2009 and covered diagnostic use and pediatric growth hormone deficiency. What follows is therefore the position taken by physicians prescribing on this axis in a clinical setting — a clinical judgment, not a regulatory document. That distinction is the reason the list has to be stated at all.

Treated as absolute — not a candidate for this therapy:

• A prior allergic reaction to sermorelin, particularly anaphylaxis
• Pregnancy, a planned near-term pregnancy, or breastfeeding
• Active malignancy
• Significant hypothalamic-pituitary structural disease or an intracranial lesion

Treated as relative — individual assessment rather than a blanket rule:

• Uncontrolled or untreated thyroid disease, whether under- or over-active
• Diabetes, prediabetes or insulin resistance — see the monitoring section below, because this one also governs what happens after starting
• Significant liver or kidney disease
• Cancer in remission, including at five years — appropriately handled in collaboration with the treating oncologist rather than decided in isolation

Separately, and independent of clinical suitability: sermorelin is prohibited by the World Anti-Doping Agency. For a competitive athlete under WADA-adherent rules it is a disqualifier, regardless of who prescribed it or why. If you compete under any anti-doping code, resolve that before anything else on this page matters ⁶.

Why Sermorelin Is Taken at Night

This is the most-asked question about sermorelin administration, and the answer is about working with your physiology rather than against it.

Your pituitary releases growth hormone in pulses, and the largest of those pulses occurs during slow-wave (deep) sleep, usually in the first few hours after falling asleep. Sermorelin directly activates GHRH receptors in the pituitary and stimulates growth hormone release — that is why GEREF could be used as a diagnostic challenge. It is not merely amplifying an endogenous sleep signal.

Evening dosing is often chosen to align administration with normal nocturnal growth hormone physiology. Controlled evidence that bedtime dosing produces better adult outcomes is limited, and we are not aware of a direct comparison establishing that other timings are less effective. Follow the timing on your prescription rather than a general rule found online.

Poor sleep, untreated sleep apnea and chronic short sleep are worth evaluating and treating because they affect health, recovery and daytime function — not because sermorelin necessarily cannot work without good sleep, which is not something the evidence establishes.

Why on an Empty Stomach

Sermorelin is typically taken with an interval after eating, particularly after meals containing fat or a large carbohydrate load.

Elevated blood glucose and insulin blunt growth hormone release — a well-described physiological relationship. Injecting shortly after a substantial meal means the stimulus lands while your body is actively suppressing the response you are trying to produce.

Follow the meal interval on your prescription and pharmacy label. Food, glucose and circulating fatty acids can influence growth hormone responses, but no single fasting interval has been established across compounded formulations and protocols.

Storage: Why Refrigeration Matters

Sermorelin is a peptide, and peptides are structurally fragile in ways small-molecule drugs are not. The activity depends on the molecule holding its shape. Heat, light and agitation can cause it to degrade or aggregate, and an aggregated peptide is both less active and — as FDA has noted regarding peptide preparations generally — a potential immunogenicity concern.

That is why storage matters. It is also why the specifics have to come from your label rather than from this page. Concentration, diluent, excipients, container and dating differ between compounding pharmacies, and a temperature or handling rule that is right for one preparation can be wrong for another.

Six things your dispensing label or pharmacy should tell you. If any is missing, ask before you use the product:

1. The storage temperature range, and whether it changes after reconstitution
2. Whether the product may be frozen — for most it must not be
3. Whether reconstitution is required, and with which diluent and what technique
4. The beyond-use date assigned to this exact preparation. A beyond-use date and a manufacturer expiry are different things — do not substitute one for the other, or borrow dating from another pharmacy's product
5. Whether a prepared syringe may sit at room temperature before injection, and for how long
6. What to do about travel and cold storage — and specifically whether a vial may contact a frozen pack, since direct contact can freeze the product

One general point does hold across peptides: do not shake. Agitation is a well-recognized way to damage a peptide, so where mixing is required it is normally done gently — but follow the method your pharmacy specifies.

If a vial has been left out, has changed appearance, or has become cloudy or discolored when it should be clear, contact your pharmacy rather than using it.

Where and How to Inject

Historical GEREF and most current compounded prescriptions use subcutaneous injection — into the fat layer beneath the skin, not into muscle. Products marketed as sermorelin can differ in form, so use only the route stated for the exact product you were dispensed. Common subcutaneous sites:

• Abdomen, avoiding roughly a two-inch radius around the navel
• Outer thigh
• Back of the upper arm
• Upper outer buttock

Rotate sites between injections. Repeated use of one spot can increase local irritation and tissue change, which may make injections less comfortable and absorption less consistent over time. A simple rotation pattern is easier to keep to than an ad-hoc one.

These parts do not vary by formulation, and they matter more than most people realize:

• Use a new sterile needle and syringe for every injection. Never reuse or share them, and never re-enter a vial with a used needle
• Wash your hands and use clean technique; disinfect the vial stopper where your product has one
• Inspect before use. If the solution has changed appearance, or is cloudy or discolored when it should be clear, contact your pharmacy rather than using it
• Place used needles and syringes straight into a proper sharps container — not household rubbish

Your clinician or pharmacy will demonstrate technique. If you have never self-injected, ask for a demonstration rather than working from a video — technique errors are common and easily corrected in person.

Why Does Sermorelin Sting?

A brief stinging or burning sensation on injection is common and usually has a mundane explanation:

• Injecting straight from the refrigerator. Cold solution stings. But whether a prepared syringe may be allowed to warm, and for how long, is formulation-specific and is not a decision to make yourself — follow your label or ask the dispensing pharmacy
• Injecting too quickly. A slower, steadier push is more comfortable
• The excipients. Some compounded preparations include preservatives or buffers that sting slightly
• Injection depth. Too shallow — into the skin rather than the fat beneath — causes more discomfort
• Site overuse. Returning to the same spot leads to increasing discomfort

Brief stinging is expected. Persistent pain, spreading redness, warmth, swelling, drainage, fever or feeling generally unwell is not — that pattern can indicate infection or another clinically important injection-site reaction, and warrants prompt contact with your clinician.

Frequency and Cycling

Sermorelin is commonly dosed daily or on a most-days schedule, sometimes with scheduled breaks. Both the frequency and any cycling pattern are clinical decisions, and the rationale varies by patient.

Use only the frequency stated on your prescription. No standard cycling schedule for chronic compounded adult use has been established. Do not add breaks, make up missed injections, or change frequency without your prescriber.

What Gets Monitored, and Why

The dose is only half of the decision. What determines whether it continues, changes or stops is what gets measured — before starting, and at intervals afterwards. Monitoring is the part that actually governs the dose.

Before starting, the useful picture is broad rather than a single number. Reasonable baseline assessment on this axis covers a blood count and metabolic panel including HbA1c, lipids, thyroid function, and sex hormones — testosterone and DHEA, and FSH, LH, estradiol and progesterone in women — together with blood pressure and body composition. The point is not to find one marker to chase. It is to know what was true before anything changed, so that a later change can be interpreted at all.

IGF-1 is not necessarily part of that baseline, which is worth pausing on. In clinical practice on this axis, IGF-1 and fasting insulin are commonly treated as discretionary measurements taken at the clinician's judgment, rather than routine ones. IGF-1 is the number most often produced online as proof that sermorelin is working — so it is telling that the clinicians who prescribe on this axis do not necessarily measure it at all. A marker that moves is not the outcome you were seeking. See does sermorelin work for why a rising IGF-1 is a laboratory result rather than a benefit.

Afterwards, reassessment is targeted rather than a repeat of everything. A review at around three months typically asks specific questions — has IGF-1 responded, has fasting insulin worsened — rather than rerunning the whole panel. The full baseline panel is generally repeated annually. Where clinic access allows, body composition and blood pressure are practical to track more frequently, monthly being common.

Measurement informs decisions; it does not establish causation. A body-composition or laboratory change over months of treatment can reflect diet, training, sleep, weight change, fluid shifts or the passage of time. No validated adult dose-response protocol exists for compounded sermorelin, so no number here can be read as proof the drug did something.

What Would Change the Dose — or Stop It

Dose and frequency are typically fairly stable once set. This is not a ladder to be climbed, and "more" is not a treatment goal.

Where it does change, an upward adjustment in dose or frequency may be considered when review — usually around three months, or sooner if something warrants it — suggests an inadequate response, and where a trial of higher dosing with continued monitoring is judged reasonable.

What would stop it, roughly in order of how often each arises:

1. An untoward reaction — either a local injection-site response or a systemic allergic reaction.
2. Lack of response to the therapy
3. A decision to try a different regimen after a three-, six- or other-month cycle
4. Less commonly, signs of worsening insulin resistance — a rising fasting insulin, hyperglycemia — identified at review, calling for stopping or a change of regimen with continued monitoring

That fourth one deserves more attention than it usually gets. Growth hormone raises blood glucose and impairs insulin sensitivity — the systematic review of growth hormone in healthy older adults found problems with glucose metabolism among the adverse effects, alongside soft-tissue swelling and joint pain. So the axis marketed most heavily for fat loss is one whose monitoring includes watching for deterioration in glucose regulation. Those two things are not in tension by accident; they are the same physiology viewed from two directions. See sermorelin and belly fat and side effects.

Injections vs Tablets

Sermorelin is available in more than one form, and this comes up frequently.

Injectable subcutaneous administration is the route with the established pharmacology — it is how GEREF was administered, and how absorption and response are best characterized.

Oral and sublingual formulations are marketed. The pharmacological challenge is straightforward: peptides are broken down by digestive enzymes, and a 29-amino-acid peptide is not well suited to surviving the gut intact.

Sublingual routes attempt to bypass digestion by absorbing through the lining of the mouth instead. That is a real mechanism, but it asks a lot of this particular molecule: sermorelin is a peptide of about 3.36 kDa (roughly 3,358 g/mol) ⁵ — substantially larger than the small, relatively lipophilic molecules that cross the oral mucosa most readily. Size alone does not make sublingual absorption impossible, but it does make formulation and direct human bioavailability data essential rather than optional.

The mass figure is for the sermorelin peptide itself; it says nothing about any particular salt, excipient system or finished formulation. Comparative bioavailability data for sermorelin formulations is limited, and equivalence should not be assumed.

If you are offered a non-injectable form, it is fair to ask what data supports its absorption.

Missed Doses

Use the missed-dose instruction supplied with your own prescription. Where no instruction is given, ask the prescriber or pharmacy rather than working it out yourself.

One rule holds regardless: do not double a dose to make up for a missed one unless your prescriber has explicitly told you to. Missing an occasional dose is not an emergency. Mention any recurring pattern at review, since it affects how your response should be interpreted.

If you miss doses frequently, that is worth solving practically rather than tolerating — an evening routine that reliably works beats a theoretically ideal schedule you cannot keep to.

Red Flags — Contact Your Clinician

• Fever, spreading redness, warmth, swelling or pus at an injection site — possible infection
• Persistent pain at an injection site beyond the brief expected stinging
• Hard lumps or dimpling of the skin at injection sites — suggests inadequate site rotation
• Difficulty breathing, facial or throat swelling, widespread hives — call 911
• Persistent headaches, visual changes, or swelling of hands and feet — see side effects
• Solution that is cloudy, discolored or contains particles — do not use; contact your pharmacy

Get Started with JumpstartMD

Correct administration matters more than most people expect. Formulation-specific storage, injection technique and adherence determine whether the preparation you were dispensed is actually handled and given as intended. Evening dosing is commonly chosen to align treatment with nocturnal growth hormone physiology, though controlled evidence that a particular clock time produces better adult outcomes is limited.

JumpstartMD was founded in 2007 by Stanford-trained physicians. You are seen face-to-face by licensed clinicians — in person at 14 California locations or online across California. When a clinician prescribes any injectable medicine, the dispensing label and a demonstrated technique should govern how it is given, rather than a leaflet or a video.

Every plan begins with lab screening and InBody® body composition scanning, repeated at visits. Measurements of that kind can inform safety and continuation decisions and can flag contributors worth investigating. They do not establish that a medicine caused an observed change, and no validated adult dose-response protocol exists for compounded sermorelin.

Sermorelin is supplied as a compounded preparation, not an FDA-approved finished drug: GEREF was historically approved for diagnostic use and pediatric growth hormone deficiency — not adult sleep, recovery, body-composition or healthy-aging goals — and controlled evidence for those adult outcomes remains limited.

Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.

Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Related Articles

• Sermorelin: What It Is and How It Works — the main guide
• Sermorelin Side Effects and Safety — interactions and who should avoid it
• Sermorelin vs HGH
• Menopause Insomnia — if poor sleep is limiting your results
• Peptide Therapy: What It Is and Who It's For